Back to search

Article

A case report of a dramatic response to Afatinib in a patient with advanced adenosquamous carcinoma lung cancer (ASC) harboring EGFR L861R

2022-04-22

Abstract excerpt

Lung cancer is a malignant tumor with high incidence and mortality in China. Furthermore, non-small cell lung cancer(NSCLC) accounts for more than 85%. About 30-40% of Asian populations carry epidermal growth factor receptor (EGFR) gene mutations. EGFR mutations mainly occur in exon 18-21, and the common mutations are exon 19 deletions (19del), L858R, which are all sensitive to EGFR tyrosine kinase inhibitors(EGFR...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
39022805-c0c1-55b7-a608-d703b93eacef
DOI
10.21203/rs.3.rs-1572588/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A case report of a dramatic response to Afatinib in a patient with advanced adenosquamous carcinoma lung cancer (ASC) harboring EGFR L861RDOI 10.21203/rs.3.rs-1572588/v1
The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations.Semantic proximity
Afatinib, an effective treatment for patient with lung squamous cell carcinoma harboring uncommon EGFR G719A and R776C co-mutations.Semantic proximity
Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma.Semantic proximity
Successful treatment of Afatinib plus Apatinib using for a lung adenocarcinoma patient with HER-2 V659D mutation: a rare case report.Semantic proximity
Successful treatment with an EGFR tyrosine kinase inhibitor Afatinib in a patient with combined small-cell lung Cancer with EGFR mutation.Semantic proximity
Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib.Semantic proximity
Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718V mutation-mediated resistance towards osimertinib: a case report and literature review.Semantic proximity
Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs.Semantic proximity
Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.Semantic proximity
The safety of afatinib for the treatment of non-small cell lung cancer.Semantic proximity
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.Semantic proximity
Long-term response to afatinib in an elderly patient with uncommon epidermal growth factor receptor mutation-positive lung adenocarcinoma.Semantic proximity
Select a neighboring publication to make it the new centre.